Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test

pill-bottles

January 18, 2012  source: MedCity News

Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.

The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.

. . .
→ Read full post: Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test

Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test

Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.

September 9, 2011  source: originally published in the San Francisco Business Times

Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.

Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.

A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and . . .
→ Read full post: Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test

Why Dear Abby loves this company (and you should, too)

Gene Security Network

Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.

In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)

Claremont Creek Ventures portfolio company AssureRx Health expands senior management team

AssureRX

It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team

Moving Quickly from an Idea to a Product

July 1, 2011  source: Genetic Engineering & Biotechnology News by Brad Webb

Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare

It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product

Recording of “Technology Transfer in the 21st Century” webcast available

John Steuart

John Steuart was a panelist at The Deal’s webcast audio seminar:

Technology Transfer in the 21st Century, on May 12, 2011

(also participating as a panelist – Jeff Jensen, CEO, Fluxion Biosciences Inc. a Claremont Creek Ventures portfolio company)

A recording of the seminar is now available  to play online or download through 8/12/2011.

Click here to access the recording. The slides from the webcast are . . .
→ Read full post: Recording of “Technology Transfer in the 21st Century” webcast available

Claremont Creek Ventures portfolio company GSN’s testing technology helps couple achieve their dream of a healthy child

April 5, 2011    source: Gene Security Network press release

Gene Security Network (GSN) welcomes the birth of the first baby to be born following the use of GSN’s novel Parental SupportTM technology for single gene preimplantation genetic diagnosis (PGD) and concurrent 24-chromosome screening. This test allows couples who are at risk to have children with genetic disease to undergo embryo testing during an in vitro fertilization (IVF) cycle in order to . . .
→ Read full post: Claremont Creek Ventures portfolio company GSN’s testing technology helps couple achieve their dream of a healthy child

Claremont Creek Ventures portfolio company, Tibion Corporation announces new $10 Million financing round, new Board Chairman & Board Members

March 1, 2011  source: Enhanced Online News (EON)

- Three Arch Partners, Hambrecht & Quist lead financing, join board - Initial investor Claremont Creek Ventures also participates -

Tibion Corporation, the privately held Silicon Valley firm transforming stroke rehabilitation with its robotic Bionic Leg, announced today the successful closure of a $10.175 million financing round, a new board of directors, and a new board chairman.

“The new financing will enable us to . . .
→ Read full post: Claremont Creek Ventures portfolio company, Tibion Corporation announces new $10 Million financing round, new Board Chairman & Board Members

mHealth – Potentially Valuable, But Not Ready For Primetime

A version of this article was originally published February 21, 2011 in The Health Care Blog Follow comments on the original blog post

mHealth – otherwise known as mobile healthcare – sounds like just what the doctor ordered to help make healthcare delivery cheaper and more effective. And since the Internet today essentially resides in everybody’s pocket, we have what amounts to a last-three-feet problem.  So I’m not sure mHealth is ready for primetime, . . .
→ Read full post: mHealth – Potentially Valuable, But Not Ready For Primetime

Medical Device and Diagnostic Industry Q&A with Ted Driscoll

October 2010  source: Medical Device & Diagnostic Industry online

The MX Q&A: Ted Driscoll, Claremont Creek Ventures

Fledgling device companies can get a leg up with VC firms by developing a product that is ‘unique and protectable,’ says Tibion’s anchor investor.

The cofounders of Tibion Bionic Technologies may want to send a thank-you note to Will Smith for helping their start-up get off on the right foot in 2004. Ted Driscoll, a . . .
→ Read full post: Medical Device and Diagnostic Industry Q&A with Ted Driscoll